Prostate Cancer Survival: Enzalutamide Edges Out Abiraterone Prostate Cancer Survival: Enzalutamide Edges Out Abiraterone

Men with metastatic disease who received enzalutamide demonstrated a small but significant survival benefit. The study was published as a preprint and has not yet been peer reviewed.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news